deltatrials
Completed PHASE3 NCT00057330

HerpeVac Trial for Young Women

A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who Are HSV-1 and -2 Seronegative

Sponsor: GlaxoSmithKline

Updated 9 times since 2017 Last updated: Jul 26, 2018 Started: Jan 14, 2003 Primary completion: Aug 22, 2009 Completion: Aug 22, 2009

This PHASE3 trial investigates Herpes Simplex Infection and is currently completed. GlaxoSmithKline leads this study, which shows 9 recorded versions since 2003 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

9 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE3

Show 4 earlier versions
  1. Sep 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Jun 2018 — Sep 2018 [monthly]

    Completed PHASE3

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Arkansas City, United States, Athens, United States, Atlanta, United States, Augusta, United States, Aurora, United States, Austin, United States, Baltimore, United States, Bardstown, United States, Baton Rouge, United States and 57 more location s